Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Movicol Paediatric Chocolate oral powder 6.8g sachets
0106040M0BBAJAB
|
Movicol | Macrogol 3350 | Gastro-Intestinal System | 13,171 |
|
HydraMed night eye ointment preservative free
21300000709
|
HydraMed night eye ointment preservative free | Eye Products | Appliances | 13,110 |
|
Ferrous sulfate 325mg modified-release tablets
0901011P0AAAKAK
|
Ferrous sulfate | Ferrous sulfate | Nutrition and Blood | 13,088 |
|
Equasym XL 10mg capsules
0404000M0BCADAU
|
Equasym | Methylphenidate hydrochloride | Central Nervous System | 13,078 |
|
Morphine 30mg modified-release tablets
0407020Q0AAALAL
|
Morphine sulfate | Morphine sulfate | Central Nervous System | 13,074 |
|
Quetiapine 50mg tablets
0402010ABAABHBH
|
Quetiapine | Quetiapine | Central Nervous System | 13,072 |
|
Trazodone 50mg/5ml oral solution sugar free
0403010X0AAAFAF
|
Trazodone hydrochloride | Trazodone hydrochloride | Central Nervous System | 13,062 |
|
Cardioplen XL 2.5mg tablets
0206020F0BKACAD
|
Cardioplen | Felodipine | Cardiovascular System | 13,061 |
|
Altrajuce liquid (4 flavours)
0913011M0BCABAG
|
Altrajuce ready to serve 1.5 kcal/ml juice style | Ready to serve 1.5 kcal/ml juice style (0913011) | Nutrition and Blood | 13,055 |
|
Altraplen Energy liquid (4 flavours)
0913011N0BBABAI
|
Altraplen ready to serve 1.5 kcal/ml milkshake | Ready to serve 1.5 kcal/ml milkshake (0913011) | Nutrition and Blood | 13,045 |
|
Co-dydramol 20mg/500mg tablets
0407010N0AAAHAH
|
Co-dydramol | Co-dydramol (Dihydrocodeine/paracetamol) | Central Nervous System | 13,042 |
|
Ondansetron 8mg tablets
0406000S0AAACAC
|
Ondansetron hydrochloride | Ondansetron hydrochloride | Central Nervous System | 13,039 |
|
Opticrom Allergy 2% eye drops
1104020T0BBAEAA
|
Opticrom | Sodium cromoglicate | Eye | 13,034 |
|
Dexamethasone 0.1% eye dps 0.4ml unit dose preservative free
1104010I0AAATAT
|
Dexamethasone (Eye) | Dexamethasone | Eye | 13,032 |
|
Longtec 40mg modified-release tablets
0407020ADBEADAH
|
Longtec | Oxycodone hydrochloride | Central Nervous System | 13,032 |
|
Lamictal 200mg tablets
0408010H0BBAGA1
|
Lamictal | Lamotrigine | Central Nervous System | 13,018 |
|
Viazem XL 120mg capsules
0206020C0BNAAAU
|
Viazem | Diltiazem hydrochloride | Cardiovascular System | 13,009 |
|
Dihydrocodeine 120mg modified-release tablets
0407020G0AAAFAF
|
Dihydrocodeine tartrate | Dihydrocodeine tartrate | Central Nervous System | 13,001 |
|
Tear-Lac Hypromellose 0.3% eye drops preservative free
21300000119
|
Tear-Lac Hypromellose 0.3% eye drops preservative free | Eye Products | Appliances | 12,999 |
|
BuTrans 5micrograms/hour transdermal patches
0407020B0BEAAAH
|
BuTrans | Buprenorphine | Central Nervous System | 12,991 |
|
Oxypro 5mg modified-release tablets
0407020ADBSAAAK
|
Oxypro | Oxycodone hydrochloride | Central Nervous System | 12,984 |
|
Combisal 25micrograms/dose / 50micrograms/dose inhaler
0302000N0BLAABE
|
Combisal | Fluticasone propionate (Inhalation) | Respiratory System | 12,957 |
|
4SURE beta-ketone testing strips
0601060W0BGAAA0
|
4SURE (Reagent) (Ketone) | Ketone blood testing reagents | Endocrine System | 12,955 |
|
Clobetasol 0.05% scalp application
1304000G0AABBBB
|
Clobetasol propionate | Clobetasol propionate | Skin | 12,947 |
|
Cavilon No Sting barrier film foam 1ml applicator
23803108008
|
Cavilon No Sting barrier film foam 1ml applicator | Skin Fillers And Protectives | Stoma Appliances | 12,932 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.